Leem proposals for the 2022 presidential elections

“Building our health future together”

“Health is the central concern of the French population. It must now assume its rightful place at the centre of political decision-making”, says Leem Chairman Frédéric Collet. “The Covid crisis has taught us that no country can justifiably claim to be a major economic power if it does not possess a strong health research and manufacturing industry. It is for these reasons that the issue of the health industries must be central to the forthcoming electoral debate”.

So with three months to go before the presidential elections, Leem is putting forward the following 27 proposals (see below) for consideration by candidates under the title Building our health future together. These proposals address four key goals:

1. Make France the European leader in pharmaceuticals by providing massive support for research and innovation. The health crisis has highlighted just how much ground France needs to make up in research and innovation. It is essential now to extend the reforms already made, and expand the country's capabilities and capacities by transforming our strengths into competitive advantages.

2. Make the pharmaceutical industry the spearhead for re-industrialisation. At a time when France and Europe are becoming more aware of how much autonomy they have lost in terms of healthcare products, medicines are an even greater strategic priority, and one that is central to national ambitions for a recovery in manufacturing industry.

3. Make patient access to treatment a top national priority. The technological revolutions that are about to take place hold out great promise for the future. Pharmaceuticals account for a significant proportion of healthcare expenditure, and also represent a major investment that generates jobs, inward investment and therapeutic progress that benefits patients. France must put in place the resources it needs to become the European champion of patient access to the medicines they need and expect.

4. Reform pharmaceutical policy for greater simplicity and efficacy. The excessive number of administrative bodies in the field of pharmaceuticals and their lack of effective coordination lie at the root of chronic inefficiency. To give concrete expression to political will, it is essential to put in place a pharmaceutical policy with a modern, simple, agile and better coordinated administrative structure.
Within these 27 measures, Leem places particular emphasis on the imperative need to return to sustainable growth in order to ensure the widest-possible access to new pharmaceutical products - especially at a time when an unprecedented wave of innovations is on the horizon - and to protect and reshore our manufacturing capacity to make France more self-sufficient in healthcare products.

“In elevating the pharmaceutical industry to the level of a strategic sector, the public authorities must also ensure that they are allowed room for the growth necessary for innovation and investment”, says LEEM Chairman Frédéric Collet.

Launch of a website that compares the health programmes of presidential candidates

As part of informing public debate and highlighting how health issues are being addressed in the electoral campaign, Leem is today launching a website that compares the health programmes of candidates in the 2022 presidential elections: www.lasantecandidate.fr

This unique website scrutinises the programmes and public statements of each candidate. Users are given the opportunity to compare the stances of up to three candidates on a given theme (health industry autonomy, vaccination, care quality and relevance, access to innovation, bioethics, the attractiveness of France for inward investment, trust in science, etc.), and explore the proposals of Leem in all these areas.

Press contacts:
Stéphanie Bou - Tel.: +33 (0)1 45 03 88 38 - +33 (0)6 60 46 23 08 - e-mail: sbou@leem.org
Virginie Pautre - Tel.: +33 (0)1 45 03 88 87 – +33 (0)6 31 86 82 70 - e-mail: vpautre@leem.org
Alice Roznowiez - Tel.: +33 (0)1 45 03 88 52 – +33 (0)6 08 97 50 49 - e-mail: aroznowiedie@leem.org
Make France the European leader in pharmaceuticals by providing massive support for research and innovation

- **A clear ambition and guidance for research**
  1. Step up the publicly-funded research effort, which is undersized in France compared with its European neighbours
  2. Give the future Health Innovation Agency the power to set clear priorities for medical research
  3. Remove the barriers between academic and industrial research to facilitate development of tomorrow’s tech solutions
  4. Continue our efforts to attract more clinical trials to France

- **Embrace new digital and technological challenges**
  5. Develop an aggressive biotechnology strategy by supporting the funding and growth of French HealthTechs
  6. Develop a framework designed to attract business investment in digital technology
  7. Make France a pioneer in the integration of health data for the benefit of patients

- **Attractive tax treatment for investment in research**
  8. Target savings more directly on providing funding for the intelligence economy (academic research, biotechnology, digital and AI)
  9. Make the research tax credit scheme more attractive

Make the pharmaceutical industry the spearhead for re-industrialisation

- **Reinforce the existing industrial fabric**
  10. Introduce a fiscal policy designed to meet the challenges involved in improving national autonomy in health
  11. Produce a strategy for reshoring the production of raw materials and strategically important pharmaceutical products
  12. Introduce a one-stop shop and simplify industry specific taxation for VSEs and SMEs

- **Boost regional competitiveness**
  13. Attract research, development and manufacture of new pharmaceuticals to the regions as part of regenerating our industrial fabric
  14. Accelerate the rollout of tomorrow’s pharmaceutical manufacturing technologies (AI, digital, etc.) as part of modernising our manufacturing base

- **Offer an attractive investment framework that uses incentive measures to promote the decarbonisation of our industrial fabric in light of the environmental commitments made by the pharmaceutical industry**
- **Support the transformation of jobs already begun by the industry**
  15. Develop work/study courses with universities and graduate schools to prepare the skills of tomorrow
  16. Encourage the integration of new talent through a commitment to train 8,000 work/study trainees every year
  17. Treat employee training as a company investment

**Make patient access to treatment a top national priority**

- **Faster patient access to innovative treatments**
  18. Consolidate the early and/or accelerated access mechanisms introduced during the previous five-year period, and actively participate in the rollout of the European health technology assessment regulation

- **Fully informed guidance**
  19. Set out multi-year guidance for France's health expenditure and strategy to provide health industry actors with the forward visibility and stability required for long-term investment

- **An appropriate 'medicines’ budget**
  20. Set a healthcare product budget that meets not only healthcare needs, but also provides the funding essential for innovation

- **A framework ensuring security of supply for pharmaceuticals**
  21. Simplify the legal and regulatory frameworks to facilitate and support a more responsive and faster supply chain

- **Innovation as a lever for efficiency**
  22. Seize the opportunity presented by innovation to update our healthcare system

- **Update the care pathway**
  23. To facilitate access to screening and preventive care (e.g. extending vaccination authorisations to other healthcare actors) and promote the pharmacy care pathway to the French public as the basis for improving primary care provision

- **Consult on the financial balance of the Assurance Maladie health insurance system**
  24. By seeking savings other than those directly related to pharmaceutical products

**Reform pharmaceutical policy for greater simplicity and efficacy**

- **A policy built on coherent goals**
  25. Make pharmaceutical policy a government priority
  26. Structure this policy around the principle of overall coherence by asserting the importance of public health, scientific and manufacturing goals, rather than short-term regulatory mechanisms

- **Political guidance appropriate to achieving the ambitions of France**
  27. A governmental structure appropriate to succeeding in the challenges faced by the industry

Visit our dedicated web space at [www.leem.org](http://www.leem.org) to find out more about the actions recommended by Leem in response to these proposals